Showing 8,161 - 8,180 results of 226,405 for search '(( a ((((larger decrease) OR (a decrease))) OR (linear decrease)) ) OR ( a large decrease ))', query time: 1.00s Refine Results
  1. 8161

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”
  2. 8162

    First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation by Kairui Yue (11874403)

    Published 2022
    “…To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”
  3. 8163
  4. 8164
  5. 8165
  6. 8166
  7. 8167

    CTS-treated MCF10A cell viability is time-dependent and serum-sensitive. by Rebecca J. Clifford (497197)

    Published 2013
    “…<p>A) MCF10A (dashed line) cells incubated with 500 nM ouabain showed a time-dependent decrease in viability during CTS treatment. …”
  8. 8168
  9. 8169
  10. 8170

    Entry probability as a function of and for . by Maria R. D'Orsogna (141837)

    Published 2009
    “…(c) When the initial and final states have larger degradation rates, a maximum as a function of arises for large . …”
  11. 8171

    Bcl-2 family mRNA expression in IL-17A and IFN-γ-treated monocyte-derived DC. by Selma Olsson Åkefeldt (282869)

    Published 2013
    “…<p>(<b>A,B</b>) DC at day 0 (None) or treated 12 days with IL-17A +/− IFN-γ. …”
  12. 8172
  13. 8173
  14. 8174
  15. 8175
  16. 8176
  17. 8177

    Photoinactivation of PSD-95-4c decreases GluR2 staining with no changes in NR1 or TfR staining. by Guillermo A. Yudowski (102587)

    Published 2013
    “…Only GluR2 in the FlAsH group showed a significant decrease (16% ±5 <i>n</i> = 7). (C) PSD-95-4c distribution was not changes after FALI. …”
  18. 8178

    Local inhibition of nitrergic activity in tenotomized rats accelerates muscle regeneration by increasing fiber area and decreasing central core lesions by A.D. Seabra (6515330)

    Published 2019
    “…<div><p>Muscular atrophy is a progressive degeneration characterized by muscular proteolysis, loss of mass and decrease in fiber area. …”
  19. 8179
  20. 8180

    Plasma membrane localized KCa3.1 is decreased by DN Rab1 and Rab8, but not by Rab2 or Rab6. by Claudia A. Bertuccio (309866)

    Published 2014
    “…<p>HEK293 cells were co-transfected with BLAP-KCa3.1 and either WT, DA or DN Rabs 1, 2, 6 or 8 and plasma membrane localized KCa3.1 evaluated by specific biotinylation, streptavidin labeling and IB (see Methods). As shown in <b>A</b> and <b>C</b>, DN Rab8 (T22N) and two different DN Rab1s (N124I, S25N) decreased expression of plasma membrane KCa3.1. …”